Sample drugs could be hazards for children
NEW YORK Free drug samples may harm children’s health, according to a study published Monday in the journal Pediatrics.
The study, an analysis of a 2004 Centers for Disease Control and Prevention survey, found that low-income children and high-income children were equally likely to receive free drug samples from doctors. Of those children, 500,000 received samples of drugs that were later revealed to cause possible health problems. The drugs were GlaxoSmithKline’s asthma drug Advair, Shire’s and Eli Lilly?s respective attention deficit hyperactivity disorder drugs Adderall and Strattera and Novartis?s eczema drug Elidel.
More than 38,000 children younger than 2 received Elidel, to which Novartis later had to add a warning that it was not approved for children that young.
Rite Aid reports cash dividend payout for preferred stock
CAMP HILL, Pa. Rite Aid on Monday declared a cash dividend of $0.4049 per share on its 5.5 percent Series I Mandatory Convertible Preferred Stock for the period commencing on Aug. 1, 2008 through Nov. 16, 2008.
The dividend is payable on Nov. 17, 2008 to shareholders of record as of Oct. 15, 2008, the company stated.
Deciphera, Lilly partner to test compounds in treatment of cancer
INDIANAPOLIS Eli Lilly and Deciphera Pharmaceuticals said Friday they would collaborate to investigate a group of Deciphera compounds as a potential cancer treatment.
The companies said they would investigate Deciphera’s preclinical B-Raf kinase inhibitors as cancer treatments, combining Deciphera’s drug-discovery resources and Lilly’s drug discovery, development and commercialization resources.
“This collaboration is further evidence of Lilly’s ongoing commitment to oncology research,” Lilly vice president for discovery research and clinical investigation Dr. William Chin said. “We look forward to working with Deciphera to leverage their B-Raf kinase inhibitor program, with the ultimate goal of developing promising drug candidates for cancer patients.”
As part of the deal, Lilly will obtain exclusive worldwide rights to any products developed as part of the collaboration, while Deciphera will receive an upfront payment and research funding, as well as up to $130 million in development, regulatory and sales milestone payments.